logo
HIV-funding cuts could drive millions of deaths

HIV-funding cuts could drive millions of deaths

Yahoo27-03-2025

When you buy through links on our articles, Future and its syndication partners may earn a commission.
We could see up to 10.8 million more HIV cases than anticipated in the next five years if planned cuts to international HIV funding take place.
This surge in infections in low- and middle-income countries would contribute up to 2.9 million more HIV-related deaths by 2030.
These disturbing figures come from a new modeling study published March 26 in the journal The Lancet HIV. The researchers wanted to analyze the potential impact of cuts to international funding for HIV/AIDS programs, which work to prevent both transmission and deaths related to the infection.
As of February 2025, the five top donors of this funding — the United States, United Kingdom, France, Germany and the Netherlands — have all announced significant cuts to foreign aid that threaten HIV programs worldwide. The study predicts how these cuts would impact low- and middle-income countries (LMICs), which since 2015 have relied on international sources for 40% of their HIV program funding.
"These findings are a sobering reminder that progress in the fight against HIV is not guaranteed — it is the result of sustained political will and investment," said Dr. Ali Zumla, a professor of infectious diseases and international health at University College London who was not involved in the research.
But equally, "the projected surge in new infections and deaths is not an inevitability; it is a consequence of choices being made today," Zumla told Live Science in an email. "If these funding cuts move forward, we risk unraveling decades of hard-won progress, leaving millions vulnerable and pushing global HIV goals further out of reach."
Related: We could end the AIDS epidemic in less than a decade. Here's how.
As of 2023, five donors have supplied more than 90% of the international funding for HIV programs, with the United States providing over 72% of the total. Specific populations at high risk of HIV — including people who inject drugs, men who have sex with men, female sex workers and their clients, and transgender and gender diverse people — particularly rely on these international funding sources for access to HIV prevention and testing.
Much of the U.S. funding comes from the President's Emergency Plan for AIDS Relief (PEPFAR), which is largely implemented by the Agency for International Development (USAID). However, PEPFAR and USAID were hit by an unprecedented funding pause and staffing reduction in January, following an executive order from President Donald Trump.
PEPFAR later received a temporary waiver to continue some services, including those for antiretroviral therapy (ART), the drugs that keep HIV from progressing to AIDS. These treatments must be taken consistently or the virus will rebound.
"The widespread rollout and uptake of antiretroviral therapy funded by international sources has been one of the most important factors reducing AIDS related deaths in lower income settings," said Justin Parkhurst, an associate professor of global health policy at the London School of Economics and Political Science who was not involved in the study. ART also cuts the number of new infections by suppressing the virus in people living with HIV, thus preventing transmission, he told Live Science in an email.
"In the worst-case scenario, if PEPFAR funding were ceased entirely and no equivalent mechanism replaced it, surges in HIV incidence could potentially undo nearly all progress achieved since 2000."
However, despite the waiver, PEPFAR's services still haven't resumed as normal, given the waiver didn't trigger immediate funding to eligible programs and many clinics had already shuttered by the time it was issued. Even now, PEPFAR's future after the waiver's expiration remains uncertain.
Following the U.S., the next top four donors for international HIV funding are the U.K., France, Germany and the Netherlands. However, as of February 2025, each of these donors has also announced major cuts in foreign aid spending — "and more might follow," the study authors wrote.
Based on the projected cuts being made by the top five donors, the researchers used a mathematical model to predict the rates of new HIV cases and deaths. They focused their model on 26 LMICs, which together receive 49% of international HIV aid, overall, and 54% of PEPFAR aid. They then used the data from these 26 countries to extrapolate to all LMICs worldwide.
The researchers considered several scenarios in their model. The first — the "status quo" — served as a baseline, projecting the rates of cases and deaths if recent levels of HIV spending were maintained between 2025 and 2030, rather than cut. In this scenario, more than 1.8 million new infections and over 720,000 HIV-related deaths occurred in LMICs.
In the worst-case scenario the team considered, all PEPFAR funding was indefinitely stopped on Jan. 20, 2025, and no alternative funding sources emerged to fill that gap. Simultaneously, other, non-PEPFAR sources of international funding were also reduced. That scenario led to an estimated 10.8 million more cases and 2.9 million more deaths than the status quo.
Related: Single-shot HIV treatment suppresses virus 10,000-fold for months, animal study finds
This suggests that "the number of new infections in 2026 could return to 2010 levels, and by 2030 the number of new infections could surpass historical estimates," the study authors wrote. "In the worst-case scenario, if PEPFAR funding were ceased entirely and no equivalent mechanism replaced it, surges in HIV incidence could potentially undo nearly all progress achieved since 2000."
This worst-case scenario would hit sub-Saharan Africa (SSA) particularly hard — out of eight SSA countries included in the analysis, six receive over 40% of their HIV funding through PEPFAR. Children in the region could see a nearly three-fold increase in HIV infections, the authors predicted.
And outside of SSA, other vulnerable populations, such as sex workers, would be much harder hit by such cuts than the general population, showing up to a six-fold higher increase in cases than other demographics, the data suggested.
The team also looked at a less extreme scenario, modeling what would happen if new funding sources filled the gap left by PEPFAR. In this scenario, they assumed that the gap could be partially filled by 2026 and then fully filled by 2027. If that mitigation were to happen, the number of extra cases drops to 4.4 million and the extra deaths to 770,000 over the course of five years.
So while filling the gap left by PEPFAR would help substantially, that sudden loss of funding would still have devastating impacts, the study suggests.
"Modelling reveals the potential for severe consequences following abrupt stopping, with no notice, of international support aimed at stopping AIDS as a global public health threat," Dr. Catherine Hankins, a professor of global and public health at McGill University in Canada who was not involved in the study, told Live Science in an email.
According to the study authors, even if the PEPFAR gap could be filled within two years, the ripple effects would be felt for decades to come. They estimated that it would take 20 to 30 extra years of 2024-level funding to end AIDS as a public health threat.
Ambitious goals set by UNAIDS have aimed to end the threat by 2030. And historic HIV trends suggested that many of the LMICs featured in the new paper could have hit their targets by about 2036, if funding continued at past levels, the authors wrote.
"This study indicates that an abrupt termination of programmes has serious risks to human life," Parkhurst said. "Even for those who believe the US or other governments should reduce foreign aid spending in this area, there can be planning around how to do so without producing serious harm to millions of people around the world who have come to rely on the treatment."
The study suggests that, if that abrupt stop could be avoided, many lives could be spared.
The researchers looked at what would happen if PEPFAR was reinstated or "equivalently recovered" and estimated that there could be 70,000 to 1.73 million extra cases and 5,000 to 61,000 extra deaths, compared to status quo. Those estimates assume that other international funding will still be reduced, but that countries will be able to make up for some of the lost funds domestically.
RELATED STORIES
—'It is a dangerous strategy, and one for which we all may pay dearly': Dismantling USAID leaves the US more exposed to pandemics than ever
—Kids under 5 with HIV are dying at high rates. Here's why.
—'We have to fight for a better end': Author John Green on how threats to USAID derail the worldwide effort to end tuberculosis
The new study has some limitations, one being that the HIV fiscal space is "unpredictable," and the trajectory of future funding cuts is unclear. It also doesn't account for potential behavioral changes that could help prevent HIV transmission in the wake of funding cuts, and it included only 26 countries that might not be fully representative of LMICs worldwide, the study authors wrote.
But the researchers argue that, if anything, these limitations would likely cause the model to underestimate the potential impacts of the funding cuts, rather than overestimate them.
"It is paramount now to track AIDS mortality and HIV incidence while urgently reversing the cuts, mitigating the effects, and creating new funding strategies to prevent further suffering," Hankins said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Graphs that paint the picture of HIV in SA
Graphs that paint the picture of HIV in SA

News24

time39 minutes ago

  • News24

Graphs that paint the picture of HIV in SA

Eight million people are living with HIV with more than six million being on treatment. Behind these big numbers lurk a universe of fascinating epidemiological dynamics. In this special briefing, Spotlight editor Marcus Low unpacks what we know about the state of HIV in South Africa. This is part 1 of 3. Four decades ago, hardly anyone in South Africa had HIV. Today, roughly one in eight people here are living with the virus. HIV has quite simply become a routine part of life in South Africa. But thanks to the fact that antiretroviral treatment is keeping several million people alive, HIV is no longer the crisis it was at the turn of the century. For many, the virus is still an all-too-real part of their lives. It still ranks among the country's top killers. As we will see in this Spotlight special briefing, there is good and bad news. We have made massive progress in our collective fight against HIV, especially since around 2008. But, as positive as the big picture may be, there are also reasons to be worried. In the 10 sections of this special briefing, we have used lots of graphs and an interactive table to liven things up. We have drawn almost entirely on estimates from Thembisa, the leading mathematical model of HIV in South Africa and also the basis for UNAIDS' country numbers. The big picture Total PLHIV in SA Graphic: Spotlight South Africa has the world's biggest HIV epidemic. Eight million people, or 12.8% of the population, lived with the virus in 2024. Despite the massive progress we've made in the last 20 years, this absolute number has kept increasing, and, at least by this measure, the epidemic has kept getting bigger. But while more people are living with HIV, dramatically fewer people are dying of HIV-related causes than two decades ago - we've gone from 281 000 HIV-related deaths in 2005/06 to 53 000 in 2023/24. This is mainly because antiretroviral medicines have kept several million people alive who would otherwise now be dead. The rate of new infections has also declined a lot, as shown in the above graph. South Africa's HIV epidemic is closely entwined with our tuberculosis (TB) epidemic. This is because untreated HIV breaks down the immune system, which then makes people vulnerable to falling ill with TB. Accordingly, TB is the top cause of HIV-related deaths in South Africa. Recovering life expectancy Just what a big deal HIV has been in South Africa is clear from estimates of life expectancy in the country. As HIV killed more and more people through the nineties and early 2000s, life expectancy dropped precipitously from 63.2 in 1990 to 53.2 in 2004. But then, as antiretroviral treatment started keeping more and more people alive, it increased again. It stood at 66.1 in 2024. Graphic: Spotlight There is much history that is not captured in this graph. Perhaps most notably, the introduction of antiretroviral treatment in South Africa's public sector was intentionally delayed by the state's policy of Aids denialism under then-president Thabo Mbeki. While the dramatic improvement from 2005 onward is impressive, life expectancy didn't have to drop as low as it did in the first place. The blip you can see on the right of the graph is a result of the Covid-19 pandemic. While significant, the broader trend is driven by HIV and the recovery from HIV. A massive treatment programme Of the eight million people living with HIV in South Africa, about 6.2 million or roughly four in five, were on treatment in 2024. This means South Africa has the world's most extensive HIV treatment programme by some distance. We take it somewhat for granted these days, but to treat so many people is a tremendous success story for which many healthcare workers, activists, government officials, donors, and others deserve great credit. That said, it is concerning that about one in five people with the virus are not on treatment. Treatment is recommended for everyone living with the virus. Though we focus on treatment coverage here, these numbers are often split further into the UNAIDS 95-95-95 targets. READ | Trump's HIV funding cuts will hit diabetes and cervical cancer treatment hard. Here's why In 2024, 95% of people living with HIV had been diagnosed, 81.5% of those diagnosed were on treatment, and 92% of those on treatment were virally suppressed - meaning the amount of virus in their blood was below a low threshold. The key takeaway from these numbers is that the most significant gap in South Africa's HIV response is in helping people who have already been diagnosed to start and stay on treatment. *Check back tomorrow for part 2 of this series. You can also find the complete version of this #InTheSpotlight special briefing as a single page on the Spotlight website. Note: All of the above graphs are based on outputs from version 4.8 of the Thembisa model published in March 2025. We thank the Thembisa team for sharing their outputs so freely. Graphs were produced by Spotlight using the R package ggplot2. You are free to reuse and republish the graphs. For ease of use, you can download them as a Microsoft PowerPoint slide deck. Technical note: The Thembisa model outputs include both stock and flow variables. This is why we have at some places written 2024 (for stock variables) and 2023/2024 (for flow variables). 2024 should be read as mid-2024. 2023/2024 should be read as the period from mid-2023 to mid-2024.

'I refuse to give up': Michigan researchers, health officials grapple with funding cuts
'I refuse to give up': Michigan researchers, health officials grapple with funding cuts

USA Today

time6 hours ago

  • USA Today

'I refuse to give up': Michigan researchers, health officials grapple with funding cuts

'I refuse to give up': Michigan researchers, health officials grapple with funding cuts Show Caption Hide Caption Video: MSU breast cancer researcher Jamie Bernard talks about funding uncertainty MSU breast cancer researcher Jamie Bernard talks about federal funding uncertainty on Thursday, May 8, 2025, at her lab in East Lansing. Michigan public health officers say they've had to cut services and lay off workers after the Trump administration slashed funding, affecting their ability to work to stop the spread of disease. Scientists from the University of Michigan and Michigan State University say federal cuts to their research could halt development for new cancer treatments and eviscerate the scientific workforce. Using words like "devastating," "heartbreaking," and "shortsighted," Michigan public health leaders and researchers at the state's largest universities described the effects of President Donald Trump's efforts to slash federal government spending — through executive orders, cuts to federal grants, and stop work orders — and the wide-reaching fallout. Some local health departments have laid off workers and cut back on the services they can provide at regional laboratories and at community and in-school health clinics, and have seen disruptions in their ability to stop the spread of infectious disease, said Norm Hess, executive director of the Michigan Association for Local Public Health. When the U.S. Department of Health and Human Services revoked $11.4 billion in COVID-19-related grants in late March, the effects were felt across Michigan in ways that might not have been anticipated, he said. 'While everyone agrees the emergency response phase of COVID-19 is over, the funding streams created for pandemic response have been supporting laboratories monitoring other diseases around the state, from legionella to tuberculosis to measles, as well as water quality inspections and other sampling work,' Hess said. 'Federal leaders rescinded those grants, clearly thinking it was a responsible way to recover money that was being misspent. Instead, it's a great example of unintended consequences. Everyone agrees government should spend public dollars efficiently and effectively, but it appears they did not check to see what they were actually eliminating when cutting grants that had 'COVID' on the label.' Although Michigan Attorney General Dana Nessel has joined other states in challenging many of the Trump administration's cuts to federal public health and university research funding, including the $11.4 billion in COVID-19-related grants, Hess said it's too risky for local health departments to count on money that may or may not be awarded to them in the end. "You can't turn it off, and then if money comes, turn it back on," he said. Cuts hit research on the science of aging When he took office, Trump pledged to eliminate waste, fraud and abuse in federal spending, and "make America healthy again" by shifting priorities of the nation's top health agencies and taking aim at research and programs that focused on diversity, equity and inclusion. But medical researchers at Michigan State University and the University of Michigan say his administration's abrupt cuts to funding for scientific studies, clinical trials and training programs have all but gutted their life's work and could halt the development of new treatments for diseases like cancer as well as eviscerate the future scientific workforce. University of Michigan psychology professor Toni Antonucci lost the $13 million federal grant that supported her research on health disparities among aging Americans. It focused on minority populations, including African Americans, and comes at a moment in history when the U.S. population is older than it ever has been and is growing increasingly diverse. "I have never thought that politics should be involved in research, and, unfortunately, this is clearly the case here," said Antonucci, who has worked at U-M since the 1970s. "We were focusing on our most vulnerable populations, and I think that's the reason that the money was ... rescinded. "It shows a kind of shortsightedness and, in a way, vindictiveness. ... My focus was on ... how can the social relations that people have improve their health? What kinds of relationships are positive for people or negative for people? How do we increase the positive, and reduce the negative? "What are the kinds of things that universally predict better health, longer longevity? ... The point is, if you know what's influencing different groups, it gives you some insight on how to intervene both with that group and with other groups." Now, she said, that data will be lost. "If a government has policies that they want to enact, regardless of the data, then this is what you do," Antonucci said. "You just make sure there are no data. But just because you don't collect the data, that doesn't mean the association isn't still there." U-M professor: Slashed grants suggest 'you just don't matter' Gary Harper, a U-M professor of health behavior and health equity, learned in late March that his nearly $1.15 million five-year grant from the National Institutes of Health had been rescinded. "It's devastating," said Harper. "I am an openly gay man, and have been involved in activism, research, clinical work, and policy work in the HIV field for 40 years, starting out in 1985 as an old-time activist at a time when we were burying our friends every week. ... This is the first time in the history of my academic career that I've been without federal research or training funds." Harper is co-director of the SOAR at U-M, which stands for Student Opportunities for AIDS/HIV Research. It's a two-year intensive mentoring program that provides HIV-related research opportunities to undergraduate students, propelling them toward graduate school, and, eventually, the HIV research workforce. Many of those students are LGBTQ+ themselves, have disabilities, or come from low-income backgrounds, he said, but Harper noted that the program is open to anyone. "I'm a strong believer that we need to be making sure that we mentor researchers who reflect the communities that are most impacted," Harper said. More: Federal research cuts would rock Michigan economy, halt clinical trials, those affected say More: Trump's budget cuts could cost Michigan universities more than $200 million Discovering that the NIH canceled SOAR's grant funding "ripped me apart," Harper said. "We have one more cohort to get through their senior year." He said he won't let the Trump administration win and cancel the program before they graduate. "Basically, what they're saying is, 'We don't want to spend any money on you because you just don't matter,' " Harper said. " 'Your life has no value.' ... Well, I refuse to give up on them." Harper and SOAR's co-director are scrambling together the money themselves to pay for the final year of the program. Slowly, he said, that is coming together, but his other work through the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Intervention has also been targeted by the federal cuts. A study on transgender youths was canceled, he said, and funding for the leadership group that oversees equity and inclusion in all ATN studies also was eliminated. He also lost grant funding to study gay and bisexual men in Kenya living with HIV. Still, he said, "I'm not going to let this get me down. "I try and show power and strength and resilience to the students, to give them hope that this, too, shall pass. This is a moment in time, but this is not your entire life. ... Your lives do matter. You are special and you are perfect, just the way you are." Breast cancer prevention studies in limbo The Trump administration isn't taking aim solely at research that fits its definition of DEI, said Jamie Bernard, an associate professor of pharmacology and toxicology at Michigan State University. "What I don't really think is being well communicated is that cancer research is also being threatened," said Bernard, who began studying interventions to prevent breast cancer in 2016, when her mother, Pamela O'Brien, was diagnosed with the disease at 61 years old. "This is something that Democrats and Republicans have always supported. In fact, we've come so far in the treatment of breast cancer due to federal funding, we diagnose women earlier. There's lots of options for treatment, and really, this research has saved a lot of lives and brought health care costs down." Her work is now focused on the environmental and lifestyle factors that can increase a woman's risk of getting aggressive breast cancers. "Not all breast cancers are curable, so that's what I really set off to focus on," she said, explaining that her work involves understanding how to kill cancer cells that are resistant to treatment and discovering new drug therapies. Earlier this year, she applied to renew a $2.07 million federal grant funded by the National Institutes of Health along with a new, $2.79 million grant, but both have been held up for months in a cloud of uncertainty. The initial reviews of her grants were postponed but eventually got through the first stage of the process; they now await the second step of review. There remain no guarantees. "How are they going to choose what they fund?" she said. "I don't know what's going to happen, really. So, we are in a time of uncertainty. Grant funding has always been uncertain. It's always been competitive, but there's always been a process and an infrastructure that researchers have relied on." Bernard runs a research lab at MSU, where a team of scientists are working to 'stop breast cancer from ever starting in the first place or prevent it so much that you've delayed it and you die of some other natural cause before you have to deal with cancer," she said. "I am in a place where I don't know if I should be accepting students in the fall. What's my next move? Am I still allowed to study what I've been studying? So it's a confusing time, a frustrating time, a time of high anxiety in our department of pharmacology and toxicology.' Bernard said the NIH canceled a grant for a graduate student from Puerto Rico who is Hispanic, and had applied through a mechanism that provided funding for predoctoral students who are disabled, identify as Black, Hispanic, American Indian or Alaska Native, or who are from socioeconomically disadvantaged backgrounds. "Just simply because she was a minority, the grant mechanism that she applied with, they withdrew it," Bernard said. "The white woman in my lab, her grant is going to be reviewed. ... It's so awful." The work they're doing, she said, "really should be bipartisan, nonpartisan — not even partisan. It's freaking cancer research." Ph.D. student reexamines future in scientific research The political climate is chasing Alex Chapman, a Ph.D. student at MSU who is studying migraines and pain, away from a career in academia. Chapman, 24, who is originally from Richmond, Virginia, secured a federal grant studying a neuropeptide that's upregulated in people with migraines, before Trump took office in January. Many of her friends and colleagues haven't been so lucky. "Science is being so vilified that I'm considering careers in other places or different avenues because it's just hard to see a future in a place that doesn't value science at all," she said. "It's heartbreaking. ... My career options are kind of dwindling, and the more time that passes, the more fellowships and different opportunities just keep becoming defunded," Chapman said, noting that a fellowship she was eyeing through the U.S. Agency for International Development (USAID) has been axed. She considered shifting toward public policy work, helping government leaders understand "why we should fund pain research," but then she attended a symposium and heard a woman who works in public policy speak about the cuts there, too. "She was like, 'This is a great fellowship. It's been defunded. This was an awesome fellowship. It's been defunded,' " Chapman said. When entrepreneur Elon Musk, who headed the new Department of Government Efficiency early in the Trump administration, criticized the use of federal dollars on scientific studies of legumes and aggression in hamsters, Chapman said, it showed that he couldn't see the full impact of the work. "If you just simplify it like that, maybe it does seem silly, but you're looking at the small picture," she said. "The point of research is to zoom out and look at the bigger picture. When you understand the best process of planting beans or why certain strains of corn are more susceptible to different fungi, you help people more effectively and efficiently plant food. This will help us in the face of climate change. "If you understand why a hamster is aggressive after ingesting a certain substance, you understand the role of that substance and how it could potentially affect humans." That small-picture view — and the cuts made because of it — could have generational impacts on the United States and the world, Chapman said. "This isn't just shutting down one study that focuses on hamsters fighting," she said. "It's preventing a new generation of scientists from coming into the (field), which is going to stunt our growth as a nation, which is going to prevent new ideas from happening, which is going to lead to ... horrible damage that would take years, if not decades, to recover. "People are afraid to come out and criticize this because of the way the government has treated them, especially foreign students. When it gets to the point where the government can strike fear in your heart if you speak out against them, especially about something regarding science, it's a very scary place to be." Local public health departments rattled, services cut Nick Derusha, the director and health officer of the LMAS District Health Department, which also includes Luce and Mackinac counties, said his part of the eastern Upper Peninsula has been rattled by a Trump administration stop-work order that means there's no money to run clinics that provide medicine like methadone to help people wean off opioid drugs and reduce the risk of overdose deaths in Alger and Schoolcraft counties. "We take a really holistic approach to that program," Derusha said. "We're not just providing medication-assisted treatment. We have peer recovery coaches. We have community health workers. We have a lot of staff that are there to support them in many other ways, not just the medication. "When funding is abruptly eliminated like that, we can't just drop people off the caseload. We needed to find a way for them to be able to continue to receive services or some type of off-ramp. We worked with the local hospital, and we agreed for three more months, which is kind of nearing the end here, to continue to provide those services, absent the funding. But the long-term ability of us to do that is not likely." In addition, Derusha said the LMAS department lost $512,000 a year to pay for a courier system for its laboratory services. Because the district is so sprawling — it covers four U.P. counties — when test samples need to be shipped to the regional lab in Luce County, ordinary mail often doesn't get them delivered quickly enough. Without the courier system, it means slower results for important public health testing, he said, which could delay treatments and lead to poorer outcomes. The LMAS District Health Department isn't alone. The Mid-Michigan Health Department, which includes Clinton, Gratiot and Montcalm counties, announced in April it will no longer investigate or treat latent tuberculosis infections because of "funding cuts and workforce limitations." Mental health services for school-age children are being cut, too, said Andrea Cole, president of the Ethel and James Flinn Foundation, a Detroit-based nonprofit dedicated to improving the quality, scope, and delivery of mental health services in Michigan. A $1 billion grant was terminated through the Department of Education in late April to pay for in-school social workers, counselors and other mental health professionals — even though 70% of children who receive mental health services get them through their schools, she said. "A lot of the federal cuts were to the most vulnerable and underserved populations," Cole said. "Schools are faced with the possibility of laying off those people that they hired under that grant if they don't have funding to continue it." And the students will be left without that critical mental health support when "they need it more than ever," Cole said. Hess said all of these cuts, along with proposed legislation — the Big, Beautiful Bill Act, which has passed the U.S. House of Representatives and now is under consideration in the U.S. Senate — that would slash Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, and a state Senate budget proposal that also seeks to trim funding even more, public health in Michigan could dramatically change. More: Whitmer: Trump's 'big, beautiful bill' could cost Michigan $900 million a year for food stamps More: 700,000 Michigan residents could lose health insurance under Medicaid cuts, report shows "We don't want to give the impression that the sky is falling, and that public health is going to pack up and go home," Hess said. "We've been here for 100 years, and we've seen ups and downs over the years. Health officers are used to kind of making things work, but this is sort of a unique situation. "Community residents are really going to feel this if all of these things that we are watching come to fruition. Public health will not look the same in their communities, in most places." Contact Kristen Shamus: kshamus@ Subscribe to the Detroit Free Press.

Can Tackling Addictions Reduce Medicaid Costs?
Can Tackling Addictions Reduce Medicaid Costs?

Newsweek

time8 hours ago

  • Newsweek

Can Tackling Addictions Reduce Medicaid Costs?

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Discussions around Medicaid costs have become more heated than ever in recent months as President Donald Trump's administration tries to push its budget bill through the legislative ranks. House Republicans have instructed the House Committee on Energy and Commerce to slash $880 billion in spending over the next decade, with Medicaid making up 93 percent of the committee's budget. As a result, the amount of money the federal Medicaid program needs to provide health care services for more than 70 million Americans has been under dispute, with some arguing there is significant waste and misuse of money in the system, while others have warned cuts would leave millions of vulnerable people without access to health care. While lawmakers continue debating the divisive legislation, experts have discussed with Newsweek whether there could be another way of reducing Medicaid costs—tackling substance use disorders. Medicaid enrollees with substance use disorders require significantly higher health costs than those without—around $1,200 per month on average compared to $550, according to KFF. Around 7.2 percent of Medicaid recipients age 12 to 64 have a diagnosed substance use disorder, and treatment is key to addressing overdoses, deaths and other health or social complications, KFF reported. So could tackling substance use disorders in turn reduce costs for the Medicaid program? Here's what experts told Newsweek. Photo-illustration by Newsweek/Getty/Canva Why Are Medicaid Costs Higher for Those With Substance Use Disorders? The reason Medicaid enrollees with substance use disorders have higher health costs is because they often also have additional health complications, Dr. Joshua Lynch, professor of emergency and addiction medicine at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, told Newsweek. This could be physical health conditions, such as hypertension, high cholesterol and diabetes, or mental health disorders, "which can lead to more complex health care needs," he added. Those with substance use disorders also may "experience more fragmented care and more challenging access to high quality, lower cost care and preventative services," Lynch said. They may also struggle to work, or stay in work, and this may "contribute to increased reliance on higher-cost healthcare services," he added. Many Americans with substance use disorders also go undiagnosed, Brendan Saloner, professor of health policy and management at the John Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. He added that those with substance addiction can have a lot of problems, such as the risk of overdose, or contracting blood-borne diseases like HIV or hepatitis C, as well as other issues, so "it's much better to get people into care proactively then to wait for their problems to become a crisis." The higher costs for those with substance use disorders, therefore, could "reflect the devastating physical consequences of substance use itself," Heidi Allen, professor of social work at the Columbia University School of Social Work, New York, told Newsweek, pointing to overdoses, increased vulnerability for chronic illness and exposure to infectious diseases. It's also not just about health complications, John Kelly, professor of psychiatry at Harvard Medical School and director of the Recovery Research Institute at Massachusetts General Hospital, told Newsweek. "The nature of these disorders means also that, on average, in the Medicaid population, individuals suffering from substance use disorder tend to have more social instability in terms of secure housing, employment, and criminal justice complications. These all contribute to increased costs," he said. Could Tackling Substance Use Disorders Reduce Medicaid Costs? While tackling substance use disorders may not slash Medicaid costs in the short term, as it would require investment in prevention and treatment, it could have positive economic impacts in the long run. "Prioritizing substance use treatment for enrollees might not reduce Medicaid costs in the short term, since we would expect more Medicaid enrollees to engage with treatment, which itself costs money," Allen said. However, she added that "it could certainly improve the health of enrollees, which might result in Medicaid savings down the road." If patients also have access to high-quality treatment and are able to manage their condition, "they have a lower reliance on high-cost health care such as emergency visits and inpatient hospitalizations," Lynch said. He added that other comorbidities also become more manageable, while housing stability and employment turn more achievable. "All of these will lead to a decrease in overall Medicaid spending," he said. Kelly also said he thought that tackling substance use disorders could reduce costs for Medicaid, adding that "focus on earlier intervention, and better implementation of care coordination will result in reduced use of more expensive acute medical care services, as well as prevention of the contraction of more chronic disease such as alcohol-associated liver diseases, HIV and hepatitis infections." "I am very confident that it would help to prevent some long-term costs to the program and would have a huge impact on other non-health needs like employment and reduced incarceration," Saloner said. But he added that whether it fully pays for itself, or saves money, is a more difficult question to answer. "We have some older studies showing that substance use care can offset lots of costs to society, but purely from the perspective of the Medicaid budget it's hard to say. The quality of life gains make it very cost-effective, whether or not it's cost saving," he said. Carrie Fry, professor in the department of health policy at Vanderbilt University School of Medicine, Tennessee, told Newsweek: "Research shows that addressing substance use disorder with effective, evidence-based treatments reduces Medicaid costs." In order to cut Medicaid costs, Fry said, making it easier for people with substance use disorders "to start and remain on effective treatment" would be an important step in the process. "For opioid use disorder, this means expanding availability of medications for opioid use disorder including methadone, buprenorphine, and naltrexone," she said. She added that only about half of Medicaid enrollees with an opioid use disorder receive evidence-based treatment in a given year. "So, treatment is an important first step to addressing the burden of substance use disorders in Medicaid and can reduce or prevent additional downstream costs," Fry said. She added that reducing the prevalence of substance use disorder via prevention will "require a more comprehensive approach to addressing broader social conditions that lead to increased risk of developing a substance use disorder."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store